As reported in PBR, Kemwell will build a new biopharmaceutical manufacturing facility in India. They will be in partnership with Boehringer Ingelheim (BI). Kemwell will be able to tap into BI's cell engineering services and their BI-Hex expression system for its clients. Their clients will also receive preferred status for scale up within the BI facilities in Europe for later stage manufacturing. The Kemwell facility will mirror BI upstream and downstream processes in its design and build out. The partners indicate that clients will receive "european technology at Indian prices".
Posted by Bruce Lehr Feb 26, 2010.
Comments